Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 3/20 | 0.51 |
| ▸ | HPGDS | O60760 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CHRND | Q07001 | 6/20 | 0.47 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.47 |
| ▸ | CHRNG | P07510 | 2/20 | 0.47 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.47 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4386989 | 1.00 | PTPN2 (0.52) | PTPN2PTPN1ACEHPGDSCA12 | |
| Hydrochloric Acid SCHEMBL12469709 | 0.98 | PTPN2 (0.51) | PTPN2PTPN1ACEHPGDSCA12 | |
| SCHEMBL26605060 | 0.90 | OPRD1 (0.48) | PTPN2PTPN1ACEHPGDSCHRND | |
| SCHEMBL26605068 | 0.90 | OPRD1 (0.48) | PTPN2PTPN1ACEHPGDSCHRND | |
| SCHEMBL30316218 | 0.89 | PTPN1 (0.58) | PTPN2PTPN1ACECHRNDCHRNA1 | |
| SCHEMBL6757142 | 0.87 | PTPN2 (0.52) | PTPN2PTPN1ACEHPGDSCA12 | |
| SCHEMBL7110134 | 0.87 | ACE (0.60) | ACECA1CHRNDCHRNA1CHRNG | |
| SCHEMBL3459805 | 0.87 | ACE (0.60) | ACECA1CHRNDCHRNA1CHRNG | |
| SCHEMBL7110125 | 0.87 | ACE (0.60) | ACECA1CHRNDCHRNA1CHRNG | |
| SCHEMBL479126 | 0.87 | ACE (0.60) | ACECA1CHRNDCHRNA1CHRNG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5298491-A | Derivatives of endogenous mediators, their salts, method of preparation, applications and compositions in which they are present | IMMUNOTECH (FR) | 1994-03-29 | — | — | US | claimed |
| US-9169295-B2 | Macrocycles and macrocycle stabilized peptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-27 | — | — | US | disclosed |
| EP-2627662-B1 | METHODS FOR PREPARING MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | disclosed |
| US-20130281657-A1 | MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-24 | — | — | US | disclosed |
| EP-1441724-B8 | METHODS OF INCREASING ENDOGENOUS TESTOSTERONE LEVELS | SERONO LAB (CH) | 2007-10-17 | — | — | EP | disclosed |
| EP-1441724-B1 | METHODS OF INCREASING ENDOGENOUS TESTOSTERONE LEVELS | APPLIED RESEARCH SYSTEMS (AN) | 2007-09-05 | — | — | EP | disclosed |
| EP-1282418-B1 | USE OF PYRAZOLE DERIVATIVES FOR TREATING INFERTILITY | APPLIED RESEARCH SYSTEMS (AN) | 2005-08-17 | — | — | EP | disclosed |
| EP-1441724-A1 | METHODS OF INCREASING ENDOGENOUS TESTOSTERONE LEVELS | Applied Research Systems ARS Holding S.A. (AN) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003026649-A1 | METHODS OF INCREASING ENDOGENOUS TESTOSTERONE LEVELS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-04-03 | — | — | WO | disclosed |
| EP-1282418-A2 | USE OF PYRAZOLE DERIVATIVES FOR TREATING INFERTILITY | Serono Reproductive Biology Institute, Inc. (US) | 2003-02-12 | — | — | EP | disclosed |
| WO-2001087287-A2 | USE OF PYRAZOLE DERIVATIVES FOR TREATING INFERTILITY | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-11-22 | — | — | WO | disclosed |
| EP-0457701-B1 | Derivatives of endogenous mediators, their salts, process for preparation, application and compositions containing them | IMMUNOTECH SA (FR) | 1995-02-22 | — | — | EP | disclosed |
| US-5298491-A | Derivatives of endogenous mediators, their salts, method of preparation, applications and compositions in which they are present | IMMUNOTECH (FR) | 1994-03-29 | — | — | US | disclosed |
| EP-0457701-A1 | Derivatives of endogenous mediators, their salts, process for preparation, application and compositions containing them | IMMUNOTECH S.A. (FR) | 1991-11-21 | — | — | EP | disclosed |
| US-4818683-A | Immunoassay for monoamines | IMMUNOTECH (FR) | 1989-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281657-A1 | MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES | PTMS, VIP, MTPN | PTPN2 2527/4885PTPN1 2977/4885ACE 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.